Infectious Disease Immunoassay Testing Market Size, Share Outlook, Growth Analysis Report and Forecast Trends 2026-2030

The infectious disease immunoassay market encompasses diagnostic tests that use antigen-antibody binding to detect pathogens such as HIV, hepatitis viruses, respiratory pathogens, and tropical diseases. In 2025, the market reached approximately $6.74 billion in global value, with multiple industry forecasts projecting continued expansion to roughly $8.87 billion by 2035. The market spans various product categories including reagents and kits, immunoassay analyzers, and supporting consumables used across hospitals, reference laboratories, and point-of-care settings.

• •Immunoassay technologies include ELISA, chemiluminescence immunoassays (CLIA), and rapid lateral flow tests, each serving different throughput and clinical needs
• •The market supports both clinical diagnostics and public health surveillance programs globally
• •Growth is supported by increasing adoption of high-throughput and automated immunoassay platforms in diagnostic laboratories

The market's growth trajectory of 6.63% annually is underpinned by several converging trends in global health and technology. Rising global incidence of infectious diseases, expanding healthcare access in emerging markets, and an aging population are fundamental demand drivers increasing testing volumes. Technological innovations are accelerating adoption, particularly the integration of artificial intelligence in diagnostic workflows and the development of rapid point-of-care testing solutions that deliver results in minutes.

• •AI-powered diagnostic tools are improving test accuracy, reducing processing time, and enhancing laboratory workflow efficiency
• •Point-of-care immunoassays are gaining significant traction due to their convenience, speed, and ability to decentralize testing beyond traditional laboratory settings
• •Government and institutional initiatives for large-scale infectious disease screening and pandemic preparedness programs are boosting overall market demand

The market is segmented by product type, technology, application, and geography, with reagents and kits typically representing the largest revenue segment. By technology, chemiluminescence immunoassays dominate high-volume laboratory settings due to their superior sensitivity and throughput, while lateral flow immunoassays serve point-of-care and home-testing applications. Geographically, North America holds the largest market share due to established healthcare infrastructure and high testing volumes, while Asia-Pacific represents the fastest-growing region.

• •North America leads in market share, driven by advanced healthcare systems, favorable reimbursement policies, and high disease prevalence awareness
• •Asia-Pacific is projected to grow at the fastest pace, fueled by large population bases, expanding healthcare access, and rising infectious disease screening rates
• •Key disease applications include HIV/ AIDS testing, hepatitis screening, sexually transmitted infection diagnostics, and respiratory infectious disease testing

What are the recent trends and outlook?

The infectious disease immunoassay market is expected to continue its expansion trajectory through 2035, reaching approximately $8.87 billion according to consolidated forecasts. Key trends shaping the future include the miniaturization of immunoassay devices for decentralized and home-based testing, the development of multiplex assay platforms capable of detecting multiple pathogens simultaneously, and the convergence of immunoassay and molecular diagnostic technologies. The COVID-19 pandemic permanently altered market dynamics by demonstrating the critical importance of rapid, scalable infectious disease testing.

• •Multiplex immunoassay platforms enabling simultaneous detection of multiple pathogens from a single sample are gaining increasing adoption in clinical laboratories
• •Home-based and self-testing models are expanding as consumer comfort and regulatory acceptance grow following widespread adoption during the pandemic
• •Ongoing investment in rapid diagnostic test development is driven by the persistent threat of emerging infectious diseases and the need for pandemic preparedness capabilities